SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling a total of 3,134 shares of common stock in open-market transactions on April 1–2, described as sales required to cover tax withholding on vesting restricted stock units under a “sell to cover” arrangement, rather than discretionary trades.
Sale prices ranged from about $12.55 to $13.09, with weighted averages around the reported prices. After these transactions, he holds 282,840 shares directly, which the disclosure states includes 151,034 shares issuable upon settlement of restricted stock units.
SI-BONE Inc amendment: The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting zero shares beneficially owned of SI-BONE Inc common stock, representing 0% of the class. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report ownership separately in reliance on SEC Release No. 34-39538.
SI-BONE, Inc. director Mika Nishimura reported an open-market sale of 4,100 shares of Common Stock. The shares were sold on March 12, 2026 at a weighted average price of $13.8293 per share, with individual trade prices ranging from $13.82 to $13.86.
After this transaction, Nishimura directly holds 32,716 shares of SI-BONE common stock. This figure includes 8,675 shares issuable upon settlement of restricted stock units, each of which represents a contingent right to receive one share of common stock. No option exercises or derivative transactions were reported.
SI-BONE, Inc. filed a shelf registration on February 24, 2026 to register an indefinite aggregate amount of securities for issuance and resale, to be offered from time to time after the effective date. The shelf covers common stock, preferred stock, debt securities and warrants, and contemplates both issuer and selling securityholder transactions.
The prospectus states the companys common stock trades on the Nasdaq Global Market under the symbol SIBN, with a reported last sale price of $15.62 on February 23, 2026. Terms, amounts, distribution methods and whether the company receives proceeds will be provided in future prospectus supplements.
SI-BONE, Inc. files its annual report describing a fast‑growing sacropelvic implant business that still operates at a loss. The company focuses on minimally invasive solutions for sacroiliac joint dysfunction, thoracolumbar fixation and fusion, and pelvic trauma, built around its 3D‑printed titanium iFuse product family.
Management estimates a U.S. addressable market above $3.5 billion, including about $2.4 billion for sacroiliac joint fusion and $1.0 billion for thoracolumbar fixation and fusion. Net loss narrowed to $18.9 million in 2025, down from $30.9 million in 2024 and $43.3 million in 2023, with an accumulated deficit of $450.3 million.
As of June 30 2025, non‑affiliate common stock had an aggregate market value of approximately $0.8 billion, and 44,165,287 shares were outstanding as of February 18 2026. The report highlights extensive clinical data, breakthrough device designations, CMS add‑on payments, significant competitive pressures, regulatory complexity, and a continued risk that the company may not achieve sustained profitability.
SI-BONE, Inc. reported strong fourth quarter and full-year 2025 results with improving profitability and issued 2026 guidance. Worldwide revenue reached $56.3 million in Q4 2025, up 15.0%, and $200.9 million for 2025, up 20.2%, with gross margin near 79%.
Net loss narrowed to $1.6 million in Q4 and $18.9 million for 2025, while adjusted EBITDA turned positive at $5.1 million in Q4 and $8.9 million for the year. The company generated positive operating cash flow of $1.7 million and free cash flow of $0.4 million in Q4, ending 2025 with $147.8 million in cash and equivalents and $35.6 million in borrowings.
For 2026, SI-BONE guides to worldwide revenue of $228.5–$232.5 million, implying ~14–16% growth, with gross margin of about 78% and higher positive adjusted EBITDA. The company also signed a new long-term lease for larger facilities and promoted CFO Anshul Maheshwari to Chief Operating Officer.
SI-BONE, Inc. reporting person Anthony J. Recupero reported multiple open-market sales of common stock on February 17, 2026 totaling 21,049 shares at weighted-average prices around the mid‑$15 range. The filing states these shares were sold under a “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units, and therefore were not discretionary trades. After these sales, Recupero reported ownership of 243,418 shares of common stock, which the footnotes state includes 83,423 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. reported that executive Michael A. Pisetsky, SVP of Operations & Administration and Chief Legal Officer, received several stock awards and sold shares primarily to cover taxes. On February 16, 2026, he acquired 58,720 shares of common stock and two additional grants of 9,787 shares each as restricted stock unit awards, at a stated price of $0.00 per share, reflecting equity compensation that will vest over multi-year periods based on service and, for one grant, relative total shareholder return performance.
On February 17, 2026, he executed open-market sales totaling 20,756 shares of common stock at weighted average prices around $15.31–$15.41 per share. Footnotes state these sales were required to satisfy tax withholding obligations from RSU vesting through “sell to cover” transactions and were not discretionary trades. After these transactions, he continued to hold a substantial share position, including 157,176 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. director and Chief Executive Officer Laura Francis reported a mix of stock awards and sales. On February 16, 2026, she acquired a total of 229,481 shares of common stock through grants and restricted stock unit awards at a stated price of $0.00 per share, which will vest over three to four years based on time and total shareholder return performance conditions. On February 17, 2026, she sold 93,475 shares of common stock in a series of open-market transactions at weighted average prices around $15.30 per share to cover tax withholding obligations from vesting restricted stock units, as disclosed in a footnote. Following these sales, she directly owned 544,369 shares, including 414,439 shares issuable upon settlement of restricted stock units, and an additional 351,319 shares were held indirectly by The David & Laura Joint Rev Tr.